Ebola Continues To Spread In DRC; Vaccine Shows High Efficacy But Mistrust Remains Prevalent
CIDRAP News: Ebola cases climb by 44 as vaccine trial affirms high efficacy
“The pace of the Democratic Republic of the Congo (DRC) Ebola outbreak showed no sign of slowing over the weekend, with another 20-case day, but with some good preliminary news about the efficacy of the vaccine, which officials hope to parlay into their pitches for community members to be vaccinated. And in new developments [Monday], the country’s health ministry reported 13 new cases and said the number of people vaccinated topped the 100,000 mark…” (Schnirring, 4/15).
Globe and Mail: In worsening Ebola outbreak, many Congolese are shunning Canadian-developed vaccine
“After the worst-ever week of new infections in one of the deadliest Ebola outbreaks in history, there is growing concern that the Canadian-developed Ebola vaccine is still mistrusted by many of the most vulnerable people in the crisis zone. … New data show that the experimental Ebola vaccine, developed at Winnipeg’s microbiology laboratory, has been remarkably effective in preventing the virus. … But a ‘huge portion’ of the Ebola infections are among those who refuse to take the vaccine, and nearly 10 percent of those who could be exposed to the virus are refusing to take the vaccine, according to Michael Ryan, executive director of the WHO’s health emergencies program…” (York, 4/15).
National Geographic: What’s keeping scientists from vanquishing Ebola?
“…Ebola is hard to arrest for many complicated reasons (below). But scientists keep trying — and what they learn will equip us to face this virus, and possibly worse, in the future…” (Preston, May 2019).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.